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Introduction Neurofibromatosis type 1 (NF1) affects approximately 2-3 in 10,000 worldwide. A high degree of unpredictability and variability of symptoms is among the hallmarks of NFI. This variable expressivity increases patient anxiety and is a serious problem for those conducting clinical trials. Thus, significant resources have been devoted to better describing the natural history of NF1, without much to show for the effort. We have chosen an alternative approach to increase the predictability of NF1, based on studies that have implicated symptom-specific modifier genes as important determinants of the clinical variability in NF1 (Easton et al., 1993; Szudek et al., 2000; Szudek et al., 2002; Szudek et al., 2003) . Our specific aims are to collect somatic DNAs from 1200 NF1 patients that represent the top and bottom 20% of dermal neurofibroma burden and to perform a case-control allele association study to evaluate potential hypomorphic alleles of three classes of candidate neurofibroma burden modifiers. The classes of potential modifier genes that we will evaluate are (1) genes implicated in maintaining genome stability, based on the idea that loss of the wild-type NF1 allele may be rate-limiting in tumor development, (2) genes included in so-called NF1 microdeletions, based on the observation that patients who carry microdeletions often develop large numbers of early onset neurofibromas, and (3) genes involved in signal transduction between the cell types that make up neurofibromas, based on the idea that cross-talk between neurofibroma constituent cells may be essential for tumor development.
Body
Our Statement of Work described the following aims for the first two years of this project: Obviously, the recruitment of sufficient numbers of carefully evaluated eligible patients is critically important for the eventual success of this project. A sufficient number during the first years of this project means 600 patients equally distributed over low and high neurofibroma burden categories. These 600 patients constitute our 'exploration panel', in which we will genotype the most common (>0.1 VAF) potentially hypomorphic SNPs. The exploration panel will be supplemented in later years by a independent 600 member 'validation panel', which will be used to confirm any detected allele association. The full 1200 member patient panel can also be used to detect statistically significant allele associations for less frequent SNPs.
In our first annual report we indicated that we had not included obtaining regulatory approval as a separate goal. We had not done this, because the Army Regulatory Compliance Office had previously approved our essentially identical pilot study, funded as an Idea Award in 1999. Thus, we did not anticipate it would take over 8 months to obtain approval, nor did we foresee that major changes in recruitment procedures and study design would be mandated. One problem was that the Army Compliance Office did not agree to new HIPAA-mandated language in our MGH/Partners Healthcare consent form. We did not have the authority to modify this admittedly convoluted language, and a conference call between all concerned authorities did nothing to resolve this issue. Another problem was that a previously approved method of recruiting patients who contacted us after learning about our study was no longer deemed allowable. In the end the only practical solution to both problems was our agreement to stop recruiting patients ourselves, and to henceforth restrict our analysis to de-identified DNA samples provided by collaborators. Table 1 . Collaborators and the numbers of available and to-be-recruited patients. Taken from our original grant application. Table 1 , taken from our grant application, indicates the number of available and to-be-recruited patients that six collaborators had agreed to contribute. Our own Institutional Review Board (IRB) and the Army Compliance Office ruled that DNA samples from 457 previously recruited patients were exempt and could be analyzed immediately. Most samples in this category had been promised to us by a single collaborator, Dr. Victor Mautner from Hamburg, Germany. Unfortunately, as indicated in our previous report, upon delivery 116 of the German samples turned out to be from patients who did not meet our neurofibroma burden eligibility criteria, and a further 51 samples contained no detectable DNA. Thus, only 121 German samples, 55 Spanish samples given to us by Dr. Lazaro, and 64 DNAs from patients recruited by us during our previous pilot project were available for immediate analysis. Delivery of the 50 samples promised by Dr. Messiaen continues to be delayed after her recent move from Ghent, Belgium to Dr. Korfs Department at the University of Birmingham, AL. Thus, rather than the promised 457 samples, only 240 patient samples were available for immediate analysis at the start of this study. For all but the most common SNPs, this number is not sufficient to reach statistical significance, prompting us to devote much initial effort to identifying further clinical collaborators.
Another setback was that Dr. Mautner unexpectedly communicated his unwillingness to recruit further patients without receiving significant monetary compensation. Rather than requesting support for a full time position when our budget could still be modified, his demand for financial compensation came only after our proposal was funded. This experience is among those that have stimulated our efforts to enlist additional clinical collaborators. After presenting the design of this study as a platform presentation at the 2003 annual National Neurofibromatosis Foundation consortium meeting, and as posters at the 2004 and 2005 meetings, several potential new collaborators expressed interest in helping us achieve our goals. Enthusiasm was particularly stimulated by a keynote address by Dr. Arnold Levine at the 2005 meeting. In his presentation Dr. Levine spoke about his recent human genetic studies, which identified MDM2 and AKTI SNPs associated with accelerated tumor development (Bond et al., 2004; Arva et al., 2005) . After his talk several clinicians, including Drs. Bruce Korf, Susan Huson, Meena Upadhyaya and even Victor Mautner expressed renewed enthusiasm in being part of our NF1 modifier study.
As a result of our efforts to advertise this study we have thus far signed up two major new collaborators. Thus, Cynthia MacKenzie on behalf of Dr. James Tonsgard recently obtained local IRB approval to provide us with de-identified blood samples from eligible patients seen at the University of Chicago NF clinic. In last year's progress report we also mentioned that Dr. Susan Huson had expressed interest in serving as our study coordinator in Great Britain. Dr. Huson is the author of several clinical studies of NF1 (Huson and Hughes, 1994), and has had a long interest in the role of modifier genes in determining disease outcome. At the 2005 meeting of the recently renamed Children's Tumor Foundation (CTF), Dr. Huson continued to express her interest in coordinating patient recruitment at U.K. clinics. However, her efforts to obtain local regulatory approval have been slowed by her recent move from Oxford to Manchester. Dr. Huson's latest estimate is that she will obtain regulatory approval later this year, after which the process of getting her approved by the Army Regulatory Compliance Office can start. Separately, at the 2005 CTF meeting Dr. Meena Upadhyaya (Bristol, U.K) indicated her willingness to provide us with samples from already recruited eligible patients. Many of her patients were recruited before informed consent was mandatory, so we expect that these samples will be exempt. As we have done in the past, we will work with collaborators to facilitate their IRB approval and resolve other regulatory issues. However, in general it has proven a frustratingly low process to get collaborators approved.
Bioinformatics Progress:
The second aim for years 1 and 2 of this project was to identify and prioritize SNPs in all three classes of potential neurofibroma burden modifiers. In our original proposal we described the design of relational databases to collect and manage information on potential hypomorphic alleles among a comprehensive set of genome stability genes. In year 1 we essentially completed this goal for genome stability genes (category 1), identifying 964 missense SNPs among 319 genes. For statistical and other reasons explained in our original proposal, only missense SNPs with a VAF >4% will be analyzed. Among the 964 missense SNPs in genome stability genes, 176 have a VAF >4%. This compares with 576 missense SNPs (110 >4%) in 244 candidate modifier genes that we had identified when this proposal was written. In the first year of this project we also identified a comprehensive set of highly polymorphic variable nucleotide tandem repeats and SNPs in the 1.5-2.0 MB segment deleted in patients with microdeletions (category 2) (Jenne et al., 2001). Finally, in year 1 we began the process of identifying candidate genes involved in signal transduction between the cell types that make up neurofibromas (category 3). In last year's progress report we described that as part of this effort we had generated a second set of databases to collect information on human members of the Ras GTPase superfamily, their regulators and interactors/effectors. Using a cross-species BLAST approach, we identified 159 human Ras superfamily members, 174 potential and confirmed human Ras superfamily GTPase Activating Proteins (GAPs), 155 potential and confirmed guanine nucleotide exchange factors (GEFs), and 359 GTPase effectors/interacting proteins. The PI of this proposal presented a talk about this work at the 2004 FASEB meeting on small GTPases in Snowmass, CO, which led to an invitation by Drs. William Balcher, Channing Der and Alan Hall to write the introductory chapter for the latest edition of a three book set in the Methods in Enzymology series focusing on Ras-related GTPases (Bernards, 2005) . This chapter, included 5
as Appendix 1, describes that roughly 3% of human genes code for Ras superfamily members, their regulators and effectors. The GTPase and Affiliated Protein database will be made available online at the time of publication. Based on our bioinformatics work we also wrote two reviews on the regulation of GTPase Activating Proteins (Bernards and Settleman, 2004) , and on their roles in growth factor signaling (Bernards and Settleman, 2005) . Both were published during the current funding period and are included as Appendices 2 and 3. For this reason we further expanded our database by including a comprehensive set of proteins that interact with effectors, GAPs, and GEFs, as well as a comprehensive collection of general signaling proteins, such as various receptors, 6 protein and lipid kinases, phosphatases, adaptors, among multiple other classes of proteins. Finally, we merged all information on all three potential classes of modifiers into a single pair of extensively hyperlinked human/Drosophila relational databases. The creation of these database has involved considerable effort, as is illustrated by the fact that the human database currently includes 6157 manually generated gene records, representing roughly one quarter of all human genes. The comprehensive nature of the database is further illustrated by its current size (509 megabytes), and by the fact that it includes abstracts or other information documenting 6166 unique protein-protein interactions (Figure 1 ). To provide easy access to other information sources and to allow a check on accuracy, records are hyperlinked to matching records of both Entrez Gene and the Human Protein Reference Database (Peri et al., 2004) . Currently, 1401 records include URLs for customized PubMed searches, and 47% of records (2881) include results of BLAST searches, used to identify paralogs and orthologs (Figure 2 ). While we have aimed for inclusiveness in creating our database, only about 1000 of the included genes (about 4% of all genes) fall into the categories that we plan to investigate as potential NF1 tumor burden modifiers. While it is impossible to succinctly summarize why each of these genes was flagged as a potential modifier, among them are 319 genes in the genome stability category and 17 genes residing within the NF1 microdeletion. The remainder represent various categories of signaling protein, including approximately 200 GAPs and GEFs for Ras, Rap, Ral, and Rho GTPases, approximately 100 GTPase effector proteins, and multiple proteins involved in signaling pathways that may be regulated by neurofibromin, such as pathways downstream of the EGF receptor, the Kit stem cell factor receptor, and the NGF receptor. In our database the EGF and Kit receptors are documented as interacting with 111 and 37 different proteins, respectively. Based on evidence in the scientific literature each candidate modifier has been assigned a high, medium, or low priority score. Our main goal is to genotype common missense SNPs in all of the approximately 350 high priority genes in the 600 member NF1 patient exploration panel. Only SNPs showing a positive association with high or low tumor burden would also be genotyped in the independent 600 member validation panel.
Progress towards designing and validation of SNP genotyping assays:
Aim 3 for years 1 and 2 was the design and validation of SNP genotyping assays. In our previous report we noted that in order to obtain experience with practical aspects of high throughput genotyping and data analysis, we had sought separate funding to allow us to genotype available case-control panels representing early onset (diagnosis <40 years) breast cancer patients. This work was done to test the hypothesis whether genome stability genes play roles as modifiers of breast cancer susceptibility. Similar to our proposed strategy in the NFN study, we genotyped separate exploration and validation patient/control panels for common missense SNPs in candidate modifier genes. Initially using a single nucleotide primer extension fluorescence polarization genotyping assay (Kwok, 2002) , later superseded by more robust methods, such as direct sequence analysis, allele specific PCR, or RFLP analysis, we performed >20,000 genotyping assays, analyzing missense SNPs in several genes, including BRCA I, BRCA2, ATM, TP53, and several Fanconi Anemia (FA) genes. Several observations implicate FA genes as potential breast cancer susceptibility modifiers. Among the most compelling findings, biallelic BRCA2 mutations have been reported to characterize patients of the FANCD1 complementation group (Howlett et al., 2002), and FANCA, which is the most frequently mutated FA gene, maps to a 650 kb interval which in a recent meta-analysis of breast cancer loss-of-heterozygosity studies was identified as having the second most significant P value (Miller et al., 2003) . Interestingly, we found that several FANCA SNPs showed highly significant differences in genotype distributions between cases and controls in both exploration and validation panels. For example, the two-degree of freedom P value for the FANCA T266A SNP is 0.02 in both the exploration and validation panels, resulting in a combined P value of 0.002. Another measure of statistical significance, the odds ratio of the cancer associated homozygous T266A genotype is 1.75, with a 95% confidence interval ranging from 1.32 to 2.32. Since several FANCA SNPs showed similar associations, we genotyped a total of 16 SNPs in FANCA and three immediately adjacent genes and collaborated with statistical geneticist Dr. Mark Daly at MIT to determine pair-wise linkage disequilibrium (LD) patterns and to identify a disease associated SNP haplotype (Figure 3) . Importantly, 25% of controls and 38% of patients in both our panels are homozygous for the breast cancer associated SNP haplotype. It is important in this respect that several SNPs in the haplotype are known to have different allele frequencies in different ethnic populations. However, this does not provide an explanation for the large 7 a i, differences observed between patients and controls, because at least 95% of cases and controls in both our panels are self-reported Caucasians. We are excited about this finding, because most familial clustering of breast cancer remains to be explained (Antoniou et al., 2002) , and since our finding indicates that one quarter of Caucasians are homozygous for a FANCA SNP haplotype that may confer a 1.75 odds ratio for developing early onset breast cancer.
To confirm the significance of our finding, we performed several functional assays with lymphoblast lines representing breast cancer associated and non-associated SNP haplotypes. No obvious deficiencies were found in experiments that analyzed FANCA mRNA levels by real-time PCR, aberrant splicing (one associated SNP maps near a splice branch site), or sensitivity to the DNA cross-linking agent mitomycin-C, which is characteristically elevated in cells from FA patients. The latter assay was done in collaboration with Dr. Alan d'Andrea at HMS. The fact that no functional correlate was found may reflect the fact that lymphoblasts are not breast cancer precursors. However, since we did not find a functional reason for the detected genetic association, we are currently collaborating with Drs. Matthew Freedman and David Althuler (MGH), and with Dr. Laura van het Veer (Netherlands Cancer Institute), to provide further genetic confirmation in additional European and North American breast cancer patients, including patients with different age of disease onset. We have presented these results in some detail, since they document our capacity to do this kind of study and illustrate how we would proceed to follow-up statistically significant allele associations in high and low tumor burden NF1 patients. Progress on aim 4: Although we have not yet reached the 600 patient recruitment goal that we had identified as the start of the genotyping phase, we have begun genotyping selected high priority SNPs during the past year. While 240 patients is unlikely to allow the detection of statistically significant genotype differences between low and high tumor burden patients, we started genotyping to generate preliminary data and to help convince clinical collaborators of the urgent need for additional patients. SNPs that we have analyzed include two FANCA missense polymorphisms (T266A and G501 S), the first of which tags the breast cancer associated haplotype. Both SNPs were genotyped by restriction fragment length polymorphism analysis. We also genotyped the recently reported SNP309 in the MDM2 promoter by direct sequence analysis of PCR amplified genomic DNA. SNP309 affects p53-dependent apoptotic signaling by affecting the level of MDM2 expression. We analyzed SNP309 because individuals homozygous for the G allele, which show higher levels of MDM2 expression, have been reported to exhibit accelerated tumor development (ref) . So far our results show no obvious difference in FANCA or MDM2 genotypes between high and low neurofibroma burden patients, but the number of patients genotyped is insufficient to make this a firm conclusion. 
Conclusions
At the start of this project we experienced an unexpected 8 month delay in receiving regulatory approval. Patient recruitment was also adversely impacted by the loss of one major collaborator, and by 9 the fact that some promised patient samples were not eligible or otherwise not useable. We have taken various measures to make up for the resulting shortfall in patient recruitment and we have enrolled or are in the process of enrolling several new collaborators. In the bioinformatics phase of this study we have generated a relational database of 6157 human genes, and we have used this database to identify approximately 1000 genes (4% of the total gene number) as candidate neurofibroma burden modifiers.
We have gained experience with genotyping and data analysis in a spin off project to analyze the role of genome stability genes in breast cancer development, and have started genotyping selected high priority SNPs in high and low neurofibroma burden patients. We have also selected the Illumina platform as the current high throughput genotyping procedure of choice and we plan to use this method to scale-up genotyping when sufficient patients become available.
References: representing approximately 0.5% of all genes in either species (Bernards, 2003) .
Importantly, although only about half of the potential human GAPs had been functionally analyzed, at least 85% of the studied proteins were determined to be active GAPs (Bernards and Settleman, 2004 4
The most basic function of the human and Drosophila databases is to provide overviews of the GTPase, GAP and GEF gene families. Thus, Figure 1 Since protein structure is an unreliable predictor of function, it is easier to compile lists of structurally related proteins than it is to assign proteins to functional categories.
However, among 482 genes in the latest version of the human database, 159 predict Ras superfamily members, 172 predict GAPs and GAP-like proteins, and 155 code for putative or confirmed GEFs ( Table 1 ). The total number of genes is less than the sum of these three categories, since three proteins combine GAP and GEF domains, whereas ARDI exhibits GAP activity towards its own Arf-like GTPase domain. Nevertheless, the fact that roughly 2% of the estimated 25,000 human genes predict proteins related to Ras superfamily members and their GAP or GEF regulators, serves to reemphasize the critical importance of the Ras superfamily.
The numbers in Table 1 are best estimates and may change for several reasons.
Thus, some identified genes may in fact be pseudogenes, and some excluded pseudogenes may turn out to be functional. More importantly, yet to be discovered regulators may be unrelated to presently known GAPs or GEFs. This point is illustrated by the recent discovery that members of the Dock family, which lack obvious similarity to previously characterized GEFS, can serve as GEFs for Rac, CDC42, and perhaps Rap The small GTPases of the Ras superfamily mediate This widely held view essentially relegates the GAPs to numerous biological processes through their ability to a 'secondary' role that is seemingly less significant than cycle between an inactive GDP-bound and an active that of the GEFs, which have received considerably more GTP-bound form. Among the key regulators of GTPase attention in the context of GTPase regulation. Some cycling are the GTPase-activating proteins (GAPs), studies have indicated, however, that GAPs can potenwhich stimulate the weak intrinsic GTP-hydrolysis tially function as effectors of activated GTPases [31. activity of the GTPases, thereby inactivating them.
Moreover, inhibition of RhoGAP activity has been found Despite the abundance of GAPs and the fact that to be sufficient to promote activation of Rho, and a mutations in GAP-encoding genes underlie several consequent Rho-mediated biological response, in the human diseases, these proteins have received relatively absence of extracellular stimuli [41, suggesting that little attention. Recent studies have addressed the reguGAPs might contribute more to the function of GTPases latory mechanisms that influence GAP activity. So far, than is superficially predicted by their biochemical findings suggest that GAP activity is regulated by activity. An important biological role for the GAPs is also several mechanisms, including protein-protein interindicated by the fact that several of them have been actions, phospholipid interactions, phosphorylation, implicated in human diseases (Box 1). subcellular translocation and proteolytic degradation.
The impressively large number of predicted GAPs is consistent with these proteins having a crucial role in There are at least 140 small GTPases encoded by the GTPase regulation, and their structural features indicate human genome, and the various subclasses of this protein that their activity is likely to be under stringent regulatory superfamily (including the Ras, Rho, Arf, Rab and Ran control. As we describe below, recent studies of the GTPases) have been implicated in almost all aspects of pathways that influence GAP activity suggest that the cell biology, including proliferation, differentiation, cytoGAPs are regulated by numerous mechanisms, including skeletal organization, vesicle trafficking, nucleocytoprotein-protein interactions, phospholipid interactions, plasmic transport and gene expression [1] . These small phosphorylation, subcellular translocation and proteolytic GTPases can be considered as 'molecular switches', whose cycling between active and inactive forms is regulated degradation. stringently by cellular factors [1] (Figure 1) .
The guanine nucleotide exchange factors (GEFs) comprise a large family of GTPase regulators that promote Regulatory GTP GDP the formation of active GTP-bound GTPases, whereas signals the GAPs promote GTPase inactivation by stimulating GTP-hydrolysis activity. In addition, a class of regulatory proteins, known as guanine nucleotide dissociation inhibitors (GDIs), has been identified for some subclasses of -E small GTPases. The GDIs seem to function as inhibitors of GTPase activation by preventing the dissociation of GDP from the inactive GTPase.
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The current dogma, at least in the context of signal targets transduction, proposes that GEFs are activated in Pi response to various stimuli and consequently promote
TRENDS in Cell Biology
GTPase activation. The activated GTPase undergoes a conformational change that enables it to interact with so- GTPase effectors: a group of proteins that typically bind specifically to the GTPTwo of the most common human genetic disorders associated with bound, activated form of the various small GTPases. GTPase effectors are frequently involved in eliciting a biological response to GTPase activation.
an increase in cancer risk, neurofibromatosis type 1 (NF1) and Many of them are protein kinases, and it seems that their interaction with their tuberous sclerosis complex (TSC), are caused by mutations that active GTPase can lead to both subcellular redistribution and catalytic disrupt the function of GTPase-activating proteins (GAPs). The NF1 activation of the kinase.
gene encodes neurofibromin, which functions as a GAP for Ras and Phospholipids: polarmoleculesconsistingofa long hydrophobiccarbonchain its immediate relatives [53] , whereas mutations in TSCI or TSC2 and a hydrophilic phosphate 'head' group. Phospholipids are prominent affect the function of atwo-subunit GAPfor the GTPase Rheb, which components of cellular membranes, and several types have been implicated in functions in the target of rapamycin (TOR) signaling pathway [10] . various cellular processes through their ability to regulate protein function Mutations in the gene RASA1, which encodes the first GAP to be through direct binding.
identified, p120 RasGAP, have been recently found in individuals Ras GTPase superfamily: a large group of GTP-binding proteins of roughly 20-30 kDa that are well conserved in evolution. All Ras GTPases show affected with a capillary and arteriovenous malformation syndrome sequence similarity to the Ras oncoprotein and share the property that they [54). Loss-of-function mutations in the murine ortholog of p120 bind GTP and have a relatively weak GTP hydrolyzing activity. In humans, there
RasGAP also cause vascularization defects [55] . are at least 140 predicted GTPases in this family, which can be further Oculocerebrorenal syndrome of Lowe (OCRL1) is an uncommon subdivided on the basis of sequence similarity into several classes including X-linked disease characterized by mental retardation, congenital the Ras, Rab, Ran, Rho and Arf GTPases. Note thatthe various GTPases, GAPs cataracts and renal Fanconi syndrome. The OCRL1 protein is a and GAP regulatory proteins, many of which are identified only by name in the phosphatidylinositol (4,5)-bisphosphate 5-phosphatase that context, are clearly defined in the website (http:I/cancer.mgh.harvard.edu/ tains a functional RhoGAP domain [56] . Through their ability to GAP_review.htm) with detailed descriptions of each protein.
Ubiquitin-proteasome system: a pathway for the targeted degradation of control F-actin dynamics, Rho GTPases have an important role in proteins, which represents an important mechanism for regulating protein axonal pathfinding and other neuronal functions, which might function. Proteins subject to the ubiquitin-proteasome system are typically explain why mutations in the RhoGAP oligophrenin [57] , the targeted by the covalent attachment of a polyubiquitin chain, which is then RhoGEF ARHGEF6 [58] , and the Rho effector protein PAK3 [59] are recognized by the proteasome, a large complex of proteins that carries out each associated with nonspecific X-linked mental retardation. proteolytic destruction of the ubiquitinated substrate.
Three other RhoGAPs have been implicated in disease, although in each case their causative role requires further confirmation. In brief, the gene GRAF, which encodes an oligophrenin-like RhoGAP, has
The 'GAP-ome' been found to show biallelic mutations in individuals affected with A recent survey found that at least 160 human genes are 5q-minus myeloid leukemia [60] likely GAPs (Table 1) suggests that these proteins have widespread and important roles in GTPase regulation. In fact, there could be many more GAPs encoded by the computer searches and could also contribute to the genome than are predicted by sequence homology regulation of GAP activity. Thus, the subtleties of GAP searches, because GAPs for many of the small GTPases regulation have been largely determined through the have not been biochemically established and it remains biochemical analysis of individual proteins. Below, we possible that such GAPs are encoded by distinct sequences describe recent examples of such studies that have begun possiblve yttbeieifdto elucidate the nature of GAP regulation. that have yet to be identified.
The domain organization of proteins can provide Regulation by protein interaction important clues about potential regulatory mechanisms, Among the best-studied examples of GAPs controlled by and many predicted GAPs contain various structural A iong the buddine yes oGAscontoledb motifs. As shown in Tables 1 and 2 , most potential proteinprotein interaction is the budding yeast two-component binding and lipid-binding motifs are restricted to one or GAP Bfalp-Bub2p for the Rab-like GTPase Tesnp, which two classes of GAP, with, for example, protein-binding activates a signaling pathway that controls mitotic exit [6] . ankyrin repeats only found in ArfGAPs and diacylglycerol-
The activity of Bfalp-Bub2p is regulated in several ways, binding C1 domains restricted to RhoGAPs. The most one of which involves phosphorylation of Bfalp by the common motifs among GAPs are Src homology domain 3
Polo-like kinase Cdc5p [7] . Cdc5p phosphorylation of (SH3) domains that bind proline-containing peptides, and Bfalp inhibits the GAP activity of Bfalp-Bub2p without phosphoinositide-binding pleckstrin homology (PH) affecting the binding of Temlp [8] . By contrast, the Cdc42p domains. Some GAPs also contain potential or confirmed effector protein Giclp interacts with Bub2p and prevents enzymatic domains ( Table 3 ), indicating that these its interaction with Temtp [9] . proteins might have additional functions, including These interactions might help to explain the role of effector roles downstream of activated GTPases.
Cdc42p and its regulators in mitotic exit. Yeast Bub2p A comparison of human and Drosophila GAPs precontains a TBC1 RabGAP catalytic domain. Most of the 40 viously showed that the domain organization of most GAPs human proteins that are currently predicted to include is evolutionarily conserved [5] . Although the existence of a TBC1 domains have not been studied; thus, it remains conserved domain organization can be used to make unclear what proportion of these proteins function as general predictions about potential regulatory mechanGAPs, and whether they typically function alone or with isms, such information reveals little about the intricacies partners. of the regulation of individual GAP proteins. In addition, Tuberin, which is encoded by the gene tuberous sclerosis several functional protein motifs and important regulatory complex-2 (TSC2), is a RapGAP-related protein that phosphorylation sites cannot be reliably predicted by functions as a GAP for the Rheb GTPase in the (4) 15 ( show GAP activity towards at least one GTPase. Numbers indicate how many putative GAPs include the indicated domains, with numbers in parentheses referring to proteins with confirmed GAP activity. bThe sequence of the human genome predicts more than five highly related paralogs of the pleckstrin homology (PH)-domain-containing and ankyrin-repeat-containing putative ArfGAP MRIP2, and similar numbers of the TBC1 D3-like RabGAP and RASA4-like RasGAP paralogs. There are also several genes predicting short protein segments related to the catalytic RhoGAP domain of the breakpoint cluster region (BCR) protein. Because it remains unclear how many of these paralogs represent functional genes, they are not included among the 160 proteins surveyed in this or the subsequent tables. Numbers in the RabGAP column refer to proteins that contain a putative RabGAP TBC1 catalytic domain. Also included is Rab3GAP, which does not contain a TBC1 domain. 'Included among RasGAP-like proteins is one member of the plexin family, to make note of the fact that some plexins include cytoplasmic segments related to RasGAP catalytic domains. dNumbers in the RhoGAP column include BNIP2, which predicts an unconventional RhoGAP. Three related human proteins contain both ArfGAP and RhoGAP domains. 'For details, see footnotes to Table 1 . Numerous examples of tyrosine and serine/threonine (a) (b) phosphorylation have been documented and, in several Rd 1,0r-cases, the regulatory effects of such phosphorylation have been determined. GAP phosphorylation has the potential GDý GDP R to influence GAP enzymatic function directly through conformational effects on the catalytic site, and it can also affect GAP activity indirectly by regulating the subcellular localization, the targeted degradation and, as described p190-:R:. above, the protein interactions of the GAP. Indeed, each of these phosphorylation-mediated regulatory mechanisms GTP Rho GDP Rac has been reported. . Similarly, insulin-induced Akt tion [121. Thus, the essential role of hamartin in the TOR phosphorylation of the TBC1-domain-containing protein signaling pathway might reflect its ability to prevent the AS160has been suggested to inhibitits RabGAP activity and proteasomal degradation of tuberin [10] .
Phosphorylation-mediated GAP regulation

GDP
to result in Rab-mediated translocation of the GLUT4 Other GAPs that have been suggested to be regulated glucose transporter to the plasma membrane [251. by protein interactions include RapGAP1, an isoform of A particularly interesting example of phosphorylationwhich binds several heterotrimeric G-protein'a-subunits mediated GAP regulation has been recently reported. through an amino (N)-terminal GoLoco motif [13] [14] [15] ;
MgcRacGAP seems to be involved in cytokinesis and MgcRacGAP, whose activity is inhibited by the binding of functions as a GAP for Rac and Cdc42, but not Rho. In protein regulating cytokinesis 1 (PRC1) to its catalytic addition, MgcRacGAP has been found to acquire RhoGAP domain [16] ; and CdGAP, whose RhoGAP activity is inhiactivity after phosphorylation by the Aurora B protein bited by the binding of the endocytic scaffolding protein kinase [261 ( Figure 3 ). Aurora B phosphorylates several intersectin, a brain-specific form of which contains a serine/threonine residues in MgcRacGAP in vitro, and functional RhoGEF domain [171.
phosphorylation of Ser387 is essential for its acquisition of The GAP activity of the p190-B RhoGAP is stimulated RhoGAP activity. Notably, Ser387 is situated in the by direct interaction with the small GTPase Rnd3 [18] , predicted catalytic domain of MgcRacGAP, suggesting suggesting the existence of'GTPase cascades' that involve that its phosphorylation directly affects the structure of the regulation of one GTPase by another through a GAP the catalytic site and thereby influences its ability to mediator (Figure 2 ). The GEFs have been also implicated interact with particular GTPases. in such cascades. For example, the RacGEF Tiaml can be Phosphorylation of MgcRacGAP is regulated by the cell activated by direct interaction with the activated Ras cycle, and the activation of latent RhoGAP activity by protein [191 (Figure 2) .
MgcRacGAP is required for cytokinesis. Notably, during Some GAPs are also regulated by intramolecular cytokinesis, MgcRacGAP localizes to the midbody, which interactions. For example, the PH domain of p120 RasGAP does not require phosphorylation of Ser387, raising the associates with and regulates the activity of its catalytic possibility that one (or more) of the other identified domain [20] ; and an N-terminal domain of the RhoGAP, phosphorylations of MgcRacGAP mediates its cell-cycleoligophrenin, has a role in inhibiting its RhoGAP activity dependent localization to the midbody. Through such a [21]. Many protein-protein interactions are regulated by regulatory mechanism, a single kinase could potentially specific phosphorylations but, as we describe in the next influence both the substrate specificity and the subsection, phosphorylation of GAPs can also regulate GAP cellular localization of a GAP via distinct phosphorylation function in other ways.
sites [261.
Regulation by phosphorylation Phosphorylation-mediated subcellular localization Protein phosphorylation obviously has a prominent role in Several published reports have correlated GAP phosphorylthe modulation of many proteins, including GAPs.
ation with a change in protein subcellular localization, TICB regulatory mechanism by which this phosphorylation (a) affects protein localization is unknown. For p190-B3 RhoGAP, a specific phosphorylation seems to be directly involved in localizing the protein to a membrane subdomain [28] . p190-B RhoGAP has been shown to mediate the inactivation of Rho after exposure of cells to insulin-like growth factor 1 (IGF-1). In vitro, insulin receptors can directly phosphorylate p190-B RhoGAP on Tyr306, which is situated in a peptide sequence that closely resembles the consensus phosphorylation site in several known substrates of insulin receptors. tyrosine phosphatase downmodulates its RhoGAP activity [281. As we describe in the following sections, GAP phosalthough the causal role of the phosphorylation has not phorylation can influence activity through additional been firmly established in most cases. For example, casein indirect mechanisms, for example, by regulating protein kinase I8 phosphorylates ArfGAP1, consequently promotstability and degradation, as well as sensitivity to phosing its interaction with membranes [271; however, the pholipid interactions. ARAP3 to the plasma membrane in response to P13K Analysis of three mammalian RasGAPs that are activation. Some ArfGAPs, such as ArfGAP3, GIT1 and structural orthologs of Drosophila GAP1 suggests that GIT2, do not contain obvious PH domains, but still show highly related proteins with identical overall domain phosphoinositide-dependent GAP activity, indicating that structures can be regulated in fundamentally different another region of the protein mediates lipid regulation. It ways. GAPi-related RasGAPs are characterized by the is also interesting that several of the Arf activators presence of two phospholipid-binding C2 motifs, followed (ArfGEFs), such as ARNO, contain PH domains and by a RasGAP catalytic segment and a PH-BTK domain,
show phosphoinositide-induced GEF activity [36] . Analysis of mammalian GAP1 m and GAP1P 4 BP found the Taken together, these findings suggest that phospholatter to be constitutively associated with the plasma inositides have a key role in regulating the cycling of Arf membrane and the former to translocate to the plasma GTPases by stimulating both GEF and GAP activities. membrane after activation by P13K [321. This difference Notably, the ArfGAPASAP1 is directly phosphorylated by has been attributed to different phosphoinositide-binding the tyrosine kinase Pyk2; this phosphorylation seems to specificities of the PH domains of these proteins, which alter the phosphoinositide-binding profile of ASAP1 and, share 63% identity [331.
consequently, to inhibit its ArfGAP activity [37] . Such a finding indicates that phosphorylation might be used more stimuli [42] , relatively few analyses of the regulation of generally to influence the lipid-binding ability of the GAP expression have been reported. various GAPs, and thus to influence indirectly lipidIn addition to transcriptional regulation, protein regulated catalytic activity or subcellular localization, degradation is a potential regulatory mechanism for controlling GAP activity, and several reports have recently Regulation of RhoGAPs confirmed that targeted protein destruction has an appar-A recent report demonstrated that the p190 RhoGAPs are ent role in regulating some GAPs. The RasGAP neurofialso sensitive to phospholipid regulation [38] . The two bromin has been observed to undergo rapid proteolytic p190 RhoGAPs (p190-A and p190-B) show catalytic GAP degradation via the UBIQUITIN-PROTEASOME SYSTEM upon activity toward several Rho family GTPases, including the treatment of cells with various growth factors [431. The RhoA, Racl and Cdc42. Several phospholipids, including results indicate that this regulation of neurofibromin can phosphatidylserine, Ptdlns(4,5)P 2 and phosphatidic acid, account for an observed increase in the magnitude and are effective inhibitors of p190 RhoGAP activity in vitro, duration of Ras activation in response to growth factors. Notably, phosphatidylserine and Ptdlns(4,5)P 2 have been The p120 RasGAP also seems to be regulated by proteofound to stimulate the GAP activity of p190 RhoGAPs lysis; unlike neurofibromin, however, p120 RasGAP is towards the Racl GTPase.
degraded by caspase cleavage, and an N-terminal proteoThus, phospholipids can 'switch' the GTPase substrate lytic fragment of p120 RasGAP seems to be involved in preference for a GAP, thereby providing a distinct inhibiting apoptosis [44] . mechanism for GTPase regulation by GAPs. Because
Caspase-independent cleavage of p120 RasGAP in phospholipids are not randomly distributed in cellular response to infection by coxsackievirus, a small RNA membranes, such a regulatory mechanism might be used virus, has also been described, and this cleavage seems to to determine the substrate specificity of a GAP within a correlate with an increase in Ras pathway activity [45] . particular membrane subdomain. The mechanism by which Notably, p120 RasGAP is a substrate of the herpes simplex phospholipids influence the catalytic function of the p190 virus type 2 protein kinase, IP10, and the expression of GAPs, as well as other GAPs, remains rather unclear, and this kinase is associated with an increase in Ras activity establishing the precise role of these lipids in GAP catalysis [46] . Taken together, these findings suggest that viral will probably require detailed structural studies.
infection can promote Ras activity through specific degradation or phosphorylation-mediated inhibition of a Role of membrane curvature RasGAP. The BAR domain, which is present in various proteins
The p190-A RhoGAP has been recently shown to including several ArfGAPs and RhoGAPs (Table 1) , has undergo targeted destruction via the proteasome pathway been recently found to show a crescent-like structure and [47] . In that study, it was observed that levels of p190-A potentially to function as a sensor of membrane curvature protein fluctuate during the cell cycle, with a sharp [391. Thus, GAPs containing BAR domains might be drop observed during late mitosis. It was determined specifically recruited to curved membranes, such as that p190-A undergoes ubiquitination in late mitosis, those of budding vesicles.
suggesting that regulation of RhoGAP activity via proThe assembly of COPI-coated vesicles on Golgi teolysis of RhoGAP has a role in the completion of mitosis. membranes involves the recruitment of the heptameric Several of the identified RapGAPs, including Tuberin, coatomer complex by Arfl-GTP, whereas COPI coat RapGAP1 and the papillomavirus E6 targeted protein 1 disassembly before vesicle fusion with target membranes (E6TP1) have been reported to undergo regulated proteorequires ArfGAPl-stimulated hydrolysis of Arfl-GTP.
lytic degradation [48] [49] [50] . Notably, E6TP1 is targeted for Remarkably, it has been reported that ArfGAPl-stimudegradation by the papillomavirus-encoded E6 protein, lated GTP hydrolysis by Arft and the subsequent and the ability to target E6TP1 is strictly correlated with disassembly of the COPI coat increases by more than the ability of the virus to immortalize human mammary two orders of magnitude as the curvature of the lipid epithelial cells [50, 511 . bilayer approaches that of a transport vesicle. A model that
In some cases, it seems that specific phosphorylation could explain this observation is that the interaction events provide the signal for targeted degradation of between ArfGAP1 and Arfl occurs more readily when GAPs. For example, phosphorylation of Tuberin by Akt membrane curvature increases [40] . It is important to inhibits its association with its binding partner, hamartin note, however, that ArfGAP1 does not contain an obvious (encoded by TSC1), leading to its instability and degra-BAR domain.
dation [52] . Similarly, phosphorylation of RapGAP1 by glycogen synthase kinase 3P (GSK-3p) seems to target Protein degradation RapGAP1 for ubiquitin-mediated destruction [49] . Thus, Protein abundance is an obvious mechanism by which phosphorylation-triggered, protease-mediated degradation GAP activity can be regulated. In fact, many of the genes of GAPs might be a general mechanism for rapidly identified to encode GAPs are reported to be restricted in inactivating GAP function, presumably as a means of their expression, suggesting that cell-type-specific tranpromoting the rapid activation of GTPases. scriptional elements have a regulatory role; for example, the RacGAP n-chimaerin is expressed specifically in Concluding remarks neurons [41] . But other than early studies showing that
The many members of the Ras superfamily of small expression of the RapGAP Spal is enhanced by mitogenic
GTPases have been implicated in nearly all cellular 
